Charles Smith, MD
Clinical Cardiac Electrophysiology · Baton Rouge, LANPI 1518962984
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,069 of the $29,470 with a category attached, or 68.1%. Amgen accounts for 75.8% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2023 at $14,166 and has fallen 95.2% since, to $673 in 2025.
Across 359 payments — averaging $82.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$22K
- Medtronic$3K
- Novartis$723
- Johnson & Johnson$490
- Pfizer$408
- Boehringer Ingelheim$396
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$20,06968%
- Travel & lodging$9263%
- Food & beverage$8,42429%
- Education$340%
- Other$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 56 | $22,342 |
| Medtronic(2 entities) | 83 | $2,996 |
| Novartis | 53 | $723 |
| Johnson & Johnson(2 entities) | 32 | $490 |
| Pfizer | 22 | $408 |
| Boehringer Ingelheim | 11 | $396 |
| AstraZeneca | 12 | $273 |
| Cleerly, Inc. | 6 | $211 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $205 |
| Boston Scientific | 3 | $173 |
| Abbott | 6 | $155 |
| E.r. Squibb & Sons, L.L.C. | 10 | $154 |
| Irhythm Technologies, Inc. | 5 | $98 |
| Inspire Medical Systems, Inc. | 2 | $85 |
| Janssen Scientific Affairs, LLC | 1 | $76 |
| Merck | 4 | $67 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Arbor Pharmaceuticals, Inc. | 4 | $53 |
| Abiomed | 2 | $51 |
| Novo Nordisk | 3 | $50 |
| Amarin Pharma, Inc. | 3 | $50 |
| Kowa Pharmaceuticals America, Inc. | 4 | $50 |
| Regeneron Healthcare Solutions, Inc. | 3 | $44 |
| GSK | 2 | $43 |
| Bayer | 2 | $37 |
| Gilead | 3 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Convatec Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Mindray DS USA, Inc. | 1 | $15 |
| Biosense Webster, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$21,569
- JARDIANCE$236
- Arctic Front$137
How this compares
$29,470 in reported general payments places this provider in the 65th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.
See all clinical cardiac electrophysiology providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 300 | $256,502 |
| EntrestoSacubitril/Valsartan | 134 | $140,120 |
| XareltoRivaroxaban | 89 | $84,142 |
| MounjaroTirzepatide | 79 | $83,150 |
| Repatha SureclickEvolocumab | 101 | $64,239 |
| OzempicSemaglutide | 56 | $58,531 |
| FarxigaDapagliflozin Propanediol | 69 | $48,556 |
| JardianceEmpagliflozin | 53 | $36,697 |
| Praluent PenAlirocumab | 12 | $7,698 |
| Ezetimibe | 247 | $5,992 |
| Metoprolol Succinate | 258 | $3,260 |
| Flecainide Acetate | 99 | $2,884 |
| Rosuvastatin Calcium | 157 | $1,996 |
| Atorvastatin Calcium | 183 | $1,834 |
| Losartan Potassium | 158 | $1,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $408 | $256,502300 claims |
| NovartisEntresto | $723 | $140,120134 claims |
| Johnson & JohnsonXarelto | $490 | $84,14289 claims |
| Novo NordiskOzempic | $50 | $58,53156 claims |
| AstraZenecaFarxiga | $273 | $48,55669 claims |
| Boehringer IngelheimJardiance | $396 | $36,69753 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.
Other clinical cardiac electrophysiology in Baton Rouge
- Mark PolletBaton Rouge$90K
- Joshua AymondBaton Rouge$64K
- Thomas GullattBaton Rouge$31K
- Kenneth CivelloBaton Rouge$30K
- Robert DrennanBaton Rouge$18K
- Paul DampfBaton Rouge$12K
- Wenjie XuBaton Rouge$10K
- Norman DeumiteBaton Rouge$9K
- Henry PatrickBaton Rouge$4K
- Nassir MarroucheNew Orleans$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.